{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:45:39Z","timestamp":1790829939291,"version":"4.1.0"},"reference-count":27,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2016,12,16]],"date-time":"2016-12-16T00:00:00Z","timestamp":1481846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Survival outcome of patients with peripheral T\u2010cell lymphoma\u2010not otherwise specified (<jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">NOS<\/jats:styled-content>) and angioimmunoblastic T\u2010cell lymphoma (<jats:styled-content style=\"fixed-case\">AITL<\/jats:styled-content>) who experience disease progression\/relapse remains very poor. A total of 321 patients, newly diagnosed with <jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">NOS<\/jats:styled-content> (<jats:italic>n\u00a0<\/jats:italic>=\u00a0180) or <jats:styled-content style=\"fixed-case\">AITL<\/jats:styled-content> (<jats:italic>n<\/jats:italic>\u00a0=\u00a0141) between 1999 and 2015, were analysed. Failure\u2010free survival (<jats:styled-content style=\"fixed-case\">FFS<\/jats:styled-content>) and overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) were calculated from the time of first disease progression (<jats:styled-content style=\"fixed-case\">FFS<\/jats:styled-content>1, <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>1), from second disease progression (<jats:styled-content style=\"fixed-case\">FFS<\/jats:styled-content>2, <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>2) and from third progression (<jats:styled-content style=\"fixed-case\">FFS<\/jats:styled-content>3, <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>3). With a median follow\u2010up duration of 52\u00a0months, 240 patients (135 <jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">NOS<\/jats:styled-content>, 105 <jats:styled-content style=\"fixed-case\">AITL<\/jats:styled-content>) experienced progression\/relapse. In patients with <jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">NOS<\/jats:styled-content>, the median durations of <jats:styled-content style=\"fixed-case\">FFS<\/jats:styled-content>1, <jats:styled-content style=\"fixed-case\">FFS<\/jats:styled-content>2 and <jats:styled-content style=\"fixed-case\">FFS<\/jats:styled-content>3 were 3\u00b71, 2\u00b75 and 2\u00b71\u00a0months, respectively. In patients with <jats:styled-content style=\"fixed-case\">AITL<\/jats:styled-content>, they were 5\u00b75, 2\u00b79 and 2\u00b73\u00a0months, respectively. There was no improvement in <jats:styled-content style=\"fixed-case\">FFS<\/jats:styled-content>1 and <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>1 by the time of recurrence during this period (1999\u20132004, 2005\u20132009 and 2010\u20132015). The median <jats:styled-content style=\"fixed-case\">FFS<\/jats:styled-content> after pralatrexate and romidepsin was only 3\u00b70 and 2\u00b75\u00a0months, respectively. The 5\u2010year <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> rates after salvage autologous and allogeneic transplant were 32% and 52%, respectively; while the 5\u2010year <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> rates for patients who did not undergo transplant was 10%. Further research for novel therapeutic approaches with higher efficacy and better safety profile are needed.<\/jats:p>","DOI":"10.1111\/bjh.14477","type":"journal-article","created":{"date-parts":[[2016,12,17]],"date-time":"2016-12-17T15:57:59Z","timestamp":1481990279000},"page":"750-758","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["The survival outcome of patients with relapsed\/refractory peripheral T\u2010cell lymphoma\u2010not otherwise specified and angioimmunoblastic T\u2010cell lymphoma"],"prefix":"10.1111","volume":"176","author":[{"given":"Dai","family":"Chihara","sequence":"first","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Fanale","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto N.","family":"Miranda","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor","family":"Noorani","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1824-2337","authenticated-orcid":false,"given":"Jason R.","family":"Westin","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick B.","family":"Hagemeister","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Fayad","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Romaguera","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Samaniego","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Turturro","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hun J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Alma","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan H.","family":"Fowler","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Hosing","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yago L.","family":"Nieto","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Oki","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,12,16]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.2719"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008214629544"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12659"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13628"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-7-11"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.240"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-573089"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3080"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq698"},{"key":"e_1_2_7_15_1","volume-title":"WHO Classification Tumors of Hematopoietic and Lymphoid Tissues","author":"Jaffe E.","year":"2001"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.321"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.1366"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7524"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2508"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-198209000-00008"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.4870"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08210.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08329.x"},{"key":"e_1_2_7_25_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow S.","year":"2008"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.8.1573"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14477","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:08:13Z","timestamp":1696291693000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,16]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1111\/bjh.14477"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14477","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,16]]},"assertion":[{"value":"2016-08-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-10-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-12-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}